Using our efficient recruitment techniques, adaptive study designs and integrated protocols we can run hybrid studies reducing our sponsors’ drug development time.
Accurate costs projection. We conducted a FIH study of Lumasiran in March 2016. Our team helped to accelerate drug development using adaptive study design and provide accurate cost projections through efficient recruitment. Alnylam received marketing authorisation in April 2020.
In a study for Symptomatic Transthyretin Amyloid Cardiomyopathy, Richmond Pharmacology enrolled 11% of patients in a multi-centre study involving 104 global centres.
Reliability and operational scalability. Our in-house recruitment team enrolled 92 hypertensive patients for a global study on behalf of Alnylam, fulfilling 58% of the total cohort. Our patient networks enabled us to rapidly upscale recruitment and reduce the study timelines.
By swiftly adapting strategies to suit the unique demands of individual trials, we ensure resources are invested in the most appropriate recruitment tactics. Frequently recruiting more than our allotted cohort size in multi-centre studies, we enable our sponsors to complete enrolment early.
Our dedicated in-house recruitment team delivers a personal service ensuring volunteers are engaged from the first contact to the last appointment.
Our recruitment database is arguably the largest in Europe.Read more +
We offer invaluable insight into study acceptability and suitability.Read more +
By listening to the feedback of our volunteers, we make continuous improvements to the experience of our research participants.
Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.
We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.